More specifically, one patient was diagnosed with PV, one patient with post-ET MF, two patients with primary myelofibrosis (PMF), and the remaining two with pre-fibrotic PMF; all of them were positive for the mutation JAK2 V617F. This evidence concerns the gene JAK2 and essential thrombocythemia.